Search academic texts

Information × Registration Number 0219U000970, 0117U000407 , R & D reports Title To optimize treatment in patients with metastatic breast cancer molecular subtypes adverse prognostic popup.stage_title Head Syvak Lyubov Andriyivna, Доктор медичних наук Registration Date 21-03-2019 Organization Ukrainian Research Institute of Oncology and Radiology popup.description2 The subject of the study - 135 patients with metastatic breast cancer, 65 patients with luminal in the breast cancer and 70 - with three times negative breast cancer. The purpose of the work is to increase the effectiveness of treating patients with metastatic thrice negative and luminal in the subtypes of breast cancer by applying the most effective regimens of chemotherapy based on the study of morphological and immunohistochemical predictor factors and their effect on the course of the disease. Research methods and equipment: clinical, laboratory, instrumental, statistical; Ultrasound apparatus "Aloca", hematological analyzer ВС-3000, biochemical analyzer "Vitros", spectrophotometer "Thermo", centrifuge high-speed "Biofuge", thermostat "Termit". At studying the features of lymphoid infiltration of tumor tissue in patients with three times negative RHZ it was established that high level of peritumoral CD4 + lymphocytes at the moment of diagnosis increases the risk of metastasis in patients with three times negative breast cancer on average by 1.73 times (HR 1.73, 95% ВI 1.27 - 2.37; p <0.001), while the high level of FOXP3 + lymphocytes in the immune infiltrate at the time of diagnosis suggests a decrease in the probability of relapse (HR 0.66; 95% BI 0.50 - 0.88; p = 0.005) in patients with three times negative ROI. It was found that the risk of death from RHD differed in patients with different ratios of CD8 + lymphocytes and FOXP3 + lymphocytes. In patients with metastatic breast cancer prognostically unfavorable molecular subtypes, the ratio of circulating lymphocytes expressing the activation markers of CD95 and HLA-DR corresponds to that in PCH. Instead, patients with luminal Her2 / neu negative РГЗ is characterized by a decrease in the relative number of CD25 + -cells among peripheral blood lymphocytes. Reduced expression of the ITSN2 mRNA in tumors with an unfavorable diagonosis (ЕР +/- PR +/- HER2 / neu +). Reduction of expression was observed in the total number of isoforms of ITSN2 and individually short isoform (ITSN2-S). This suggests the use of ITSN2-S as a prognostic marker of the mammary gland. There were no significant differences in the expression of ITSN2-L and TKS5-L in the analyzed samples. Product Description popup.authors А.Аскольський А.Романов В. Орел Л. Яценко Н.Верьовкіна О. Шепель С. Кукушкіна С. Лялькін Т. Тарасенко Ф. Фільчаков popup.nrat_date 2020-04-02 Close